ModerateTriple fixed-dose combination: dopamine precursor, peripheral decarboxylase inhibitor, and COMT inhibitor×Allylamine antifungal (systemic and topical)
Updated · Methodology
Mechanism
Dopa decarboxylase and catechol-O-methyltransferase (COMT) are the main enzymes that metabolise levodopa, and entacapone is eliminated after conjugation with glucuronic acid (Stalevo SmPC, European Medicines Agency, EMA). In human liver microsome studies, entacapone inhibited CYP2C9 and showed little or no inhibition of other cytochrome P450 enzymes (EMA). The US label therefore states that entacapone has the potential to affect drugs whose metabolism depends on CYP2C9. In healthy volunteers, it raised the area under the concentration–time curve (AUC) of R-warfarin by 18% on average (carbidopa, levodopa and entacapone label, US Food and Drug Administration, FDA). At least seven cytochrome P450 enzymes metabolise terbinafine in the liver, with the largest contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19 (terbinafine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Terbinafine itself inhibits CYP2D6, an enzyme that does not metabolise levodopa, carbidopa or entacapone (terbinafine SmPC, AEMPS; Stalevo SmPC, EMA). The documents do not say how terbinafine levels change with entacapone.
Symptoms
The documents describe no symptoms linked to this combination. Both documents warn about depression. During treatment with the combination, patients are watched closely for mental changes and depression with suicidal tendencies (Stalevo SmPC, European Medicines Agency, EMA). Depressive symptoms have occurred during postmarketing use of terbinafine tablets (terbinafine label, US Food and Drug Administration, FDA). Terbinafine can damage the liver and, in very rare cases, cause severe liver failure. The signs are persistent nausea, loss of appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine and pale stools (terbinafine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The combination can cause abnormal liver function tests and severe, mainly cholestatic hepatitis. Its most common adverse reactions are dyskinesia, nausea, diarrhoea, muscle pain and harmless reddish-brown discolouration of the urine (EMA).
Management
No document names this pair. The US label of the combination asks for the dose of carbidopa, levodopa and entacapone to be adjusted as clinically needed in patients who take other drugs metabolised via CYP2C9 (US Food and Drug Administration, FDA). CYP2C9 is one of the enzymes that metabolise terbinafine (terbinafine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Liver function is tested before terbinafine tablets are started and then monitored periodically, after 4–6 weeks of treatment. If liver test values rise, terbinafine is stopped at once (terbinafine SmPC, AEMPS). During long-term treatment with the combination, liver function is also assessed periodically (Stalevo SmPC, European Medicines Agency, EMA). Terbinafine is contraindicated in chronic or active liver disease (AEMPS), and the combination in severe hepatic impairment (EMA). Both documents ask for attention to mood. Patients on the combination are watched closely for depression with suicidal tendencies (EMA). During terbinafine treatment, patients are monitored for depressive symptoms (terbinafine label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Terbinafina, Terbinafina Normon 250 mg comprimidos (nº registro 68185), sección 4.4 (2026)– AEMPS, CIMA, nº registro 68185 (Terbinafina Normon 250 mg comprimidos EFG, Laboratorios Normon), revisión 10/2026, secciones 4.4 y 4.5
- FDA: Terbinafine tablets, Cipla (terbinafine) prescribing information (2025)– FDA, DailyMed setid 18b16aad-1877-4b07-b532-f0ef4843af91 (Cipla USA), versión 6, efectiva 09/2025, secciones 7 y 12.3
- EMA: Ficha técnica: Levodopa/carbidopa/entacapona (EU/1/03/260), sección 4.5 (2026)– EMA, Stalevo 100 mg/25 mg/200 mg comprimidos recubiertos con película (Orion Corporation, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03260007, consultada 03.11.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 4.7 y 5.2
- FDA: Carbidopa, levodopa and entacapone tablets (Sandoz) prescribing information (2026)– FDA, DailyMed setid 9c16c0e0-3b97-486b-b7d5-579f5853e2c5 (Sandoz Inc, NDA 021485), revised 03/2026 (version 14), sections 5.1, 5.2, 5.14, 7 and 12.3